izpis_h1_title_alt

PPIA, HRPT1, and PGK1 genes as the appropriate combination for RT-qPCR normalization in alveolar and femoral bone remodeling in olanzapine-treated rats
ID Disha Ibrahimi, Saranda (Avtor), ID Drevenšek, Gorazd (Avtor), ID Drevenšek, Martina (Avtor), ID Marc, Janja (Avtor), ID Prodan Žitnik, Irena (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,27 MB)
MD5: B47BDD6B7DE4F437C3D7F7709619697F
URLURL - Izvorni URL, za dostop obiščite https://acta.pharmaceutica.farmaceut.org/wp-content/uploads/2024/09/51124.pdf Povezava se odpre v novem oknu

Izvleček
Reliable gene expression analysis in bone remodeling studies requires an appropriate selection of internal controls, i.e. stable reference genes for the normalization of quantitative real-time PCR (RT-qPCR), the most common method used for quantifying gene expression measurements. Even the most widely used reference genes can have variable expression under different experimental conditions, or in different tissue types or treatment regimes, so selecting appropriate controls is a key step in ensuring reliable results. The aim of this research was to identify the most stable reference gene(s) for the study of olanzapine modulated bone remodeling in rats. RNA was isolated from the maxillary alveolar and femoral bones of olanzapine or placebo-treated Wistar rats and transcribed to cDNA. The expression of 12 candidate reference genes was assessed by RT‐qPCR. Their expressions were analysed using GeNorm, NormFinder, BestKeeper and delta Ct algorithms, and by the comprehensive ranking method. PPIA, HRPT1 and PGK1 were the most stably expressed reference genes and the combination of the three genes was optimal for normalization. This study is the first to identify the optimal reference genes for research in olanzapine-exposed rats, which serve as a pivotal benchmark for enhancing the accuracy and reliability of future RT-qPCR expression in bone studies.

Jezik:Angleški jezik
Ključne besede:reference genes, alveolar bone, RT-qPCR, rat, olanzapine
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
MF - Medicinska fakulteta
Različica publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:Str. 511-524
Številčenje:Vol. 74, no. 3
PID:20.500.12556/RUL-163546 Povezava se odpre v novem oknu
UDK:602.64:616
ISSN pri članku:1846-9558
DOI:10.2478/acph-2024-0029 Povezava se odpre v novem oknu
COBISS.SI-ID:206027523 Povezava se odpre v novem oknu
Datum objave v RUL:08.10.2024
Število ogledov:65
Število prenosov:7
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Acta pharmaceutica
Skrajšan naslov:Acta pharm.
Založnik:Croatian Pharmaceutical Society
ISSN:1846-9558
COBISS.SI-ID:3817585 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-ND 4.0, Creative Commons Priznanje avtorstva-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nd/4.0/deed.sl
Opis:Licenca Creative Commons Brez predelav dovoljuje uporabnikom ponovno distribucijo dela, vendar ne v spremenjeni obliki. Zahtevana je navedba avtorstva.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:referenčni geni, alveolarna kost, RT-qPCR, podgane, olanzapin, genska terapija, gensko izražanje

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0293
Naslov:Parodontalna medicina

Financer:Drugi - Drug financer ali več financerjev
Številka projekta:AD FUTURA
Naslov:AD FUTURA. Science and Education Foundation of the Republic of Slovenia,

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj